Features of lipid metabolism in patients with type 2 diabetes mellitus and gout

Abstract

The aim: To study the relationship between lipid metabolism parameters, chemerin, and adenosine monophosphate-activated protein kinase (AMPK) activity in patients with type 2 diabetes mellitus (T2DM), as well as in patients with a combined course of T2DM and gout. Materials and methods. To assess lipid metabolism disorders, 100 patients were examined and divided into 2 groups: 1st group – patients with T2DM and gout (n=70), 2nd group – patients with gout (n=30), control group (CG) – practically healthy individuals (n=20). The levels of total cholesterol (TC), triglycerides, high density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), and very low-density lipopro tein cholesterol (VLDL) were analyzed. As markers of insulin resistance (IR), the content of AMPK and chemerin was investigated. Statistical data processing was carried out using the statistical data processing program package version 8.0 STATISTICA (StatSoft Inc). The results. A significant difference was found between the levels of lipid parameters (except HDL) when comparing patients with the combined pathology of T2DM and gout, with a monocourse of gout and representatives of CG (р<0.001). It was also found that among lipidogram indicators, in all groups, an inverse correlation of AMPK value with LDL level was found (strong for patients of the 1st group and medium strength for representatives of the 2nd group and CG). Another indicator with which AMPK levels in all groups were statistically reliably correlated was TC. The presence of a direct correlation between the levels of LDL and chemerin in the 2nd group and CG, as well as the levels of TC and chemerin in patients with a combination of T2DM with gout and an inverse correlation in the other groups (all p<0.05) was established. Conclusions: Statistically significant relationships were found between lipid metabolism indicators, chemerin and AMPK activity in patients with T2DM, as well as in patients with combined course of T2DM and gout